Inhibitor Therapeutics held annual shareholder meeting, elected directors
INTI•Annual meeting results
Inhibitor Therapeutics held its annual stockholders meeting on Sept. 15, 2026.
- Stockholders selected six directors for one-year terms expiring at the 2027 annual meeting.
- Cherry Bekaert was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
- Stockholders adopted the 2025 Share Incentive Plan.
- A non-binding advisory vote endorsed executive compensation.
- Stockholders favored holding future non-binding advisory votes on executive compensation every three years.
